| __timestamp | HUTCHMED (China) Limited | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 33472000 | 581800000 |
| Thursday, January 1, 2015 | 47368000 | 671900000 |
| Friday, January 1, 2016 | 66871000 | 876700000 |
| Sunday, January 1, 2017 | 50675000 | 857900000 |
| Monday, January 1, 2018 | 78821000 | 822200000 |
| Tuesday, January 1, 2019 | 91944000 | 778200000 |
| Wednesday, January 1, 2020 | 111234000 | 512600000 |
| Friday, January 1, 2021 | 207447000 | 681000000 |
| Saturday, January 1, 2022 | 267587000 | 662200000 |
| Sunday, January 1, 2023 | 303055000 | 910700000 |
Igniting the spark of knowledge
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Viatris Inc. and HUTCHMED (China) Limited have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Viatris Inc. consistently outspent HUTCHMED, with its R&D expenses peaking at approximately 910 million USD in 2023, a 56% increase from 2014. In contrast, HUTCHMED's R&D spending grew more than eightfold, reaching around 303 million USD in 2023. This rapid growth underscores HUTCHMED's aggressive push into the global market. While Viatris maintains a steady investment, HUTCHMED's exponential increase highlights its strategic focus on innovation. As these companies navigate the competitive pharmaceutical industry, their R&D investments will likely play a pivotal role in shaping their future trajectories.
R&D Insights: How Pfizer Inc. and Viatris Inc. Allocate Funds
Bristol-Myers Squibb Company vs Viatris Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Bristol-Myers Squibb Company and HUTCHMED (China) Limited
R&D Insights: How GSK plc and Viatris Inc. Allocate Funds
R&D Insights: How Teva Pharmaceutical Industries Limited and HUTCHMED (China) Limited Allocate Funds
United Therapeutics Corporation or Viatris Inc.: Who Invests More in Innovation?
Incyte Corporation or HUTCHMED (China) Limited: Who Invests More in Innovation?
Comparing Innovation Spending: Viatris Inc. and Opthea Limited
Comparing Innovation Spending: Viatris Inc. and CRISPR Therapeutics AG
Amneal Pharmaceuticals, Inc. or HUTCHMED (China) Limited: Who Invests More in Innovation?
HUTCHMED (China) Limited vs Soleno Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for HUTCHMED (China) Limited and Viridian Therapeutics, Inc.